Get the Stockscreener App
0.60
0.82%
0.0049
Protagenic Therapeutics Inc stock is traded at $0.60, with a volume of 456.
It is up +0.82% in the last 24 hours and down -14.29% over the past month.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
See More
Previous Close:
$0.5951
Open:
$0.63
24h Volume:
456
Relative Volume:
0.00
Market Cap:
$3.79M
Revenue:
-
Net Income/Loss:
$-5.00M
P/E Ratio:
-0.7595
EPS:
-0.79
Net Cash Flow:
$-3.85M
1W Performance:
-13.13%
1M Performance:
-14.29%
6M Performance:
-62.45%
1Y Performance:
-25.00%
1-Day Range:
$0.6126
$0.63
1-Week Range:
$0.538
$0.71
52-Week Range:
$0.49
$1.87
Protagenic Therapeutics Inc Stock (PTIX) Company Profile
Name
Protagenic Therapeutics Inc
Sector
Industry
Phone
(212) 994-8200
Address
149 FIFTH AVENUE, NEW YORK
Compare PTIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PTIX | 0.6126 | 3.79M | 0 | -5.00M | -3.85M | -0.79 |
| VRTX | 446.01 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.16 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.51 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Protagenic Therapeutics Inc Stock (PTIX) Latest News
ARMISTICE CAPITAL, LLC Acquires New Stake in Protagenic Therapeu - GuruFocus.com
Protagenic Therapeutics Inc. Warrant (PTIXW) Quarterly 10-Q Report - Quartz
Protagenic Therapeutics Inc. (PTIX) Quarterly 10-Q Report - Quartz
Protagenic Therapeutics Completes Private Placement, Raises $1.275 Million - Defense World
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - AccessWire
Protagenic Therapeutics Raises $1.27M in Private Placement with Warrant Offerings | PTIX Stock News - StockTitan
Protagenic Therapeutics Raises $1.275M for Growth Initiatives - TipRanks
Protagenic Therapeutics Secures $1.275M in Private Placement - TipRanks
Protagenic Therapeutics announces $1.275 million stock sale By Investing.com - Investing.com Canada
Protagenic Therapeutics announces $1.275 million stock sale - Investing.com
Protagenic Therapeutics to sell 1.95M shares at 64c in private placement - TipRanks
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
PTIX stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
PTIX stock touches 52-week low at $0.49 amid market challenges - Investing.com Canada
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Short Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Expands By 3,669.0% - Defense World
The Williams Companies, Inc. (NYSE:WMB) Shares Acquired by Mill Creek Capital Advisors LLC - Defense World
Stephens’s latest rating for PTLO stock - Knox Daily
Petratherm Ltd Reports Key Shareholder Changes - TipRanks
ProSiebenSat.1 Media (OTCMKTS:PBSFY) Shares Up 8.7% - Defense World
A look into Prothena Corporation plc (PRTA)’s deeper side - SETE News
Views of Wall Street’s Leading Experts on Proto Labs Inc - SETE News
Top Wall Street Forecasters Revamp Progress Software Price Expectations Ahead Of Q3 Earnings - Benzinga
Pacer Advisors Inc. Has $74.14 Million Stake in Playtika Holding Corp. (NASDAQ:PLTK) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Rhumbline Advisers - Defense World
Protagonist Therapeutics Inc [NASDAQ: PTGX] Sees Increase in Stock Value - Knox Daily
Propel Hits 52-Week High on KOHO Link - Baystreet.ca
BOK Financial upgraded, Prosperity Bancshares downgraded at Truist (NASDAQ:BOKF) - Seeking Alpha
Roth/MKM flags Playtika stock’s profitability risks despite new IP additions - Investing.com Australia
Progyny Stock Faces Its Biggest Drop Ever After Losing a Major Client. Why These Analysts Like the Stock. - Barron's
Playtika (NASDAQ:PLTK) Rating Reiterated by Wedbush - Defense World
Progyny price target lowered to $25 from $37 at Cantor Fitzgerald - TipRanks
Acadian Asset Management LLC Sells 27,140 Shares of Proto Labs, Inc. (NYSE:PRLB) - Defense World
Morgan Stanley maintains positive outlook on ProLogis stock By Investing.com - Investing.com Canada
Investors who lost money with shares of Proto Labs, Inc. (NYSE: - openPR
Portage Biotech (PRTG): Wild Ride Continues, But Uncertainty Looms - BP Journal
Headlands Technologies LLC Sells 2,206 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Analyzing PTC Therapeutics Inc (PTCT) After Recent Trading Activity - Knox Daily
Check Out PTC Therapeutics Inc (PTCT)’s Trade Data Rather Than the Analysts’ Views - SETE News
A better buy-in window may exist right now for Protagonist Therapeutics Inc (PTGX) - SETE News
Bokf Na Raises Position in Kforce Inc. (NASDAQ:KFRC) - Defense World
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Needham & Company LLC Reiterates “Buy” Rating for Kornit Digital (NASDAQ:KRNT) - Defense World
Wall Street analysts’ outlook for Protagenic Therapeutics Inc (PTIX) - SETE News
Pre-market Movers: TNON, FULC, SMFL, RYDE, NTGR… - RTTNews
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Analyzing the Impact of Earnings Reports on Protagenic Therapeutics Inc Inc. (PTIX) Price Performance - The InvestChronicle
Protagenic Therapeutics (NASDAQ:PTIX) Stock Price Down 9.2% - Defense World
PTIX stock touches 52-week low at $0.6 amid market challenges - Investing.com India
Protagenic Therapeutics Inc Stock (PTIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):